Mirati Therapeutics (MRTX) PT Raised to $210 at Piper Sandler

Piper Sandler analyst Tyler Van Buren raised the price target on Mirati Therapeutics (NASDAQ: MRTX) to $210.00 (from $170.00) while maintaining an Overweight rating.

The analyst commented, "The adagrasib (formerly MRTX849) Phase Ib/II 45% ORR met investor expectations perour recent flash poll and appears improved versus sotorasib's 35%. The 96% DCR (vs.91%) and depth of tumor reductions (70% of responders with >40% vs. 50%) also appears better. While it is much too early to accurately compare mDORs, improved ORRs, DCRs, and deeper tumor reductions do typically lead to improved mDOR/mPFS. A 3% incidence of Grade 3-4 QT prolongation was reported, but it resolved without treatment, there was no recurrence/worsening, the three patients continued on study, and investigators were not concerned. We don't believe this is enough to offset the potential best-in-class efficacy advantage. We are now lowering our discount rate and increasing our PT to $210, which is primarily supported by NSCLC, some CRC, and very little for sitra. We also need to consider adding the G12D to the model given the encouraging preclinical update."

You May Also Be Interested In

• Natera (NTRA) PT Raised to $270 at BTIG
• United Airlines (UAL) PT Raised to $153 at UBS Ahead of Q2 Results
• American Airlines (AAL) PT Raised to $21 at UBS Ahead of Q2 Earnings